258 related articles for article (PubMed ID: 27806283)
21. Two distinct aggregation pathways in transthyretin misfolding and amyloid formation.
Dasari AKR; Hung I; Gan Z; Lim KH
Biochim Biophys Acta Proteins Proteom; 2019 Mar; 1867(3):344-349. PubMed ID: 30366153
[TBL] [Abstract][Full Text] [Related]
22. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.
Phay M; Blinder V; Macy S; Greene MJ; Wooliver DC; Liu W; Planas A; Walsh DM; Connors LH; Primmer SR; Planque SA; Paul S; O'Nuallain B
Rejuvenation Res; 2014 Apr; 17(2):97-104. PubMed ID: 24164623
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.
Gustavsson A; Engström U; Westermark P
Am J Pathol; 1994 Jun; 144(6):1301-11. PubMed ID: 8203468
[TBL] [Abstract][Full Text] [Related]
24. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
25. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses.
Almeida MR; Gales L; Damas AM; Cardoso I; Saraiva MJ
Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):587-96. PubMed ID: 16266291
[TBL] [Abstract][Full Text] [Related]
26. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.
Westermark P; Bergström J; Solomon A; Murphy C; Sletten K
Amyloid; 2003 Aug; 10 Suppl 1():48-54. PubMed ID: 14640042
[TBL] [Abstract][Full Text] [Related]
27. A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
Faria TQ; Almeida ZL; Cruz PF; Jesus CS; Castanheira P; Brito RM
Phys Chem Chem Phys; 2015 Mar; 17(11):7255-63. PubMed ID: 25694367
[TBL] [Abstract][Full Text] [Related]
28. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Arsequell G; Planas A
Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
[TBL] [Abstract][Full Text] [Related]
29. Structure and assembly-disassembly properties of wild-type transthyretin amyloid protofibrils observed with atomic force microscopy.
Pires RH; Saraiva MJ; Damas AM; Kellermayer MS
J Mol Recognit; 2011; 24(3):467-76. PubMed ID: 21504025
[TBL] [Abstract][Full Text] [Related]
30. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Ferreira N; Saraiva MJ; Almeida MR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875761
[TBL] [Abstract][Full Text] [Related]
31. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
32. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
33. Transthyretin microheterogeneity and molecular interactions: implications for amyloid formation.
Landreh M; Ostberg LJ; Pettersson TM; Jörnvall H
Biomol Concepts; 2014 Jun; 5(3):257-64. PubMed ID: 25372757
[TBL] [Abstract][Full Text] [Related]
34. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
Manral P; Reixach N
Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
36. Cholesterol and Sphingomyelin Uniquely Alter the Rate of Transthyretin Aggregation and Decrease the Toxicity of Amyloid Fibrils.
Ali A; Zhaliazka K; Dou T; Holman AP; Kurouski D
J Phys Chem Lett; 2023 Dec; 14(49):10886-10893. PubMed ID: 38033106
[TBL] [Abstract][Full Text] [Related]
37. The Regulatory Mechanism of Transthyretin Irreversible Aggregation through Liquid-to-Solid Phase Transition.
Duan G; Li Y; Ye M; Liu H; Wang N; Luo S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835140
[TBL] [Abstract][Full Text] [Related]
38. S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril.
Nakanishi T; Yoshioka M; Moriuchi K; Yamamoto D; Tsuji M; Takubo T
Biochim Biophys Acta; 2010 Jul; 1804(7):1449-56. PubMed ID: 20388560
[TBL] [Abstract][Full Text] [Related]
39. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
Bergström J; Gustavsson A; Hellman U; Sletten K; Murphy CL; Weiss DT; Solomon A; Olofsson BO; Westermark P
J Pathol; 2005 Jun; 206(2):224-32. PubMed ID: 15810051
[TBL] [Abstract][Full Text] [Related]
40. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
